Skip to search formSkip to main contentSkip to account menu

BMS188797

Known as: BMS-188797 
An analog of paclitaxel with antineoplastic activity. BMS-188797 binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Rationale: BMS-188797 is one of several novel taxanes in ongoing clinical development. It has superior activity in experimental… 
2006
2006
This phase I study investigated the maximum tolerated dose and pharmacokinetics of a 3-weekly administration of BMS-188797, a… 
Review
2006
Review
2006
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2005
2005
Purpose: Preclinical studies show that BMS-188797 has a broad spectrum of antitumor activity in in vitro cytotoxicity assays and… 
2005
2005
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2004
2004
BACKGROUND The development of synthetic taxanes targets at increasing solubility of the drug, improved clinical efficacy and… 
2004
2004
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2003
2003
PURPOSE The purpose of this study was to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and… 
Highly Cited
2000
Highly Cited
2000
Abstract. Purpose: Two taxane analogs, BMS-184476 and -188797, were evaluated for their in vitro cytotoxicity and in vivo…